Benzinga · Aug 27, 2026
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9.25 to $9.5.
LU
NASDAQ · LUCD
Lucid Diagnostics Inc. Common Stock
Healthcare · Medical - Devices
$0.80
Down-$0.02 (-2.07%)
Updated Sep 11, 2026, 5:52 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 117.03M
- P/E ratio
- -2.06
- Dividend yield
- 0.00%
- 52-week range
- $0.81 – $1.63
- Volume
- 1.25M
- Avg. volume
- 939.24K
Price performance
LUCD price history
1M range · 0 trading sessions · Daily adjusted prices
LUCD does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest LUCD news
The latest Smart Investors Daily articles mentioning LUCD.
Stock researchCompany · Overview
LUCD research
Overview
Company profile and research snapshot.
Company profile
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Ascendiant Capital | Buy | — |
| Aug 17, 2026 | BTIG | Buy | — |
| Jun 8, 2026 | Ascendiant Capital | Buy | — |
| May 15, 2026 | BTIG | Buy | — |
| May 15, 2026 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 18, 2026
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
Benzinga · Aug 17, 2026
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.
SeekingAlpha · Aug 13, 2026
Lucid Diagnostics Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-13. The following slide deck was published by Lucid Diagnostics Inc.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
